Are AirPods Pro hearing aids?
What the FDA's September 12, 2024 authorization of Apple's Hearing Aid Feature actually approved, who it fits, and where it falls short of a dedicated hearing aid.
Read the explainer →Our research library covers OTC hearing technology, age-related hearing loss, speech-in-noise comprehension, and the consumer decisions people face when buying their first hearing device. Every entry references public clinical or regulatory sources.
Last reviewed: May 13, 2026 · Reviewed by: Dr Jeffrey Smith, AuD, Editor-in-Chief
National Hearing Institute's research covers age-related hearing loss, FDA-regulated OTC hearing aids, speech-in-noise comprehension, the relationship between untreated hearing loss and cognitive decline, and the consumer-protection questions buyers face. Every claim traces to a public primary source — FDA guidance, NIDCD statistics, the WHO World Report on Hearing, or peer-reviewed publications in journals such as The Lancet, JAMA Otolaryngology – Head & Neck Surgery, and Trends in Hearing.
What the FDA's September 12, 2024 authorization of Apple's Hearing Aid Feature actually approved, who it fits, and where it falls short of a dedicated hearing aid.
Read the explainer →Current OTC and prescription price ranges, where the money actually goes, Costco pricing, and how to reduce out-of-pocket cost.
Read the guide →Original Medicare, Medicare Advantage, HSA/FSA, VA, Medigap, and cochlear implants — the full 2026 coverage picture.
Read the guide →What the AAO-HNS Clinical Practice Guideline and Cochrane review actually conclude. When tinnitus warrants a clinician visit rather than a consumer device.
Read the review →A careful read of the 2023 ACHIEVE randomised controlled trial and how it fits with the 2024 Lancet Commission framework.
Read the explainer →Plain-English guide to audiogram symbols, dB HL severity bands, common configurations of hearing loss, and what an audiogram cannot tell you.
Read the explainer →The 10 most common signals and when each one warrants a hearing screen.
Read the article →Sensorineural, conductive, mixed — the full anatomical breakdown of causes.
Read the article →The 14-day window, AAO-HNS 2019 guideline, and why time-to-treatment matters.
Read the article →Why unilateral loss is a clinical red flag; CROS/BiCROS and cochlear implant options.
Read the article →NIOSH 85 dBA, the 4 kHz notch, what's recoverable, and how to prevent damage.
Read the article →What's recoverable, what isn't, and what comes closest.
Read the article →High-frequency hearing loss explained — consonants, vowels, and the speech banana.
Read the article →The daily and weekly routine. HowTo schema with 7 steps.
Read the guide →Average lifespan by category, warranty coverage, and when to replace.
Read the article →Zinc-air sizes, the brown tab, rechargeable vs disposable, and life expectations.
Read the article →The binaural benefit, auditory deprivation, and when one is enough.
Read the article →How to evaluate over-the-counter hearing aids using speech clarity, comfort, usability, trial period, and warranty — not just price.
Read the guide →What the FDA's self-fitting category actually includes, how in-app hearing tests calibrate amplification, and the limits of self-fitting.
Read the explainer →What changed with the 2022 FDA OTC rule, who each category serves, and the practical differences in fitting, follow-up, and cost.
Read the comparison →About 1 in 3 U.S. adults aged 65–74 has hearing loss, and nearly half of those 75 and older do, per the NIDCD. We focus on how this gradual change affects daily life and what evidence-informed support looks like.
Since the FDA's Final Rule took effect October 17, 2022, U.S. adults 18+ with perceived mild-to-moderate hearing loss can buy regulated OTC hearing aids without a clinic visit. We track product categories, capabilities, and limitations.
The most common complaint is not "things are quieter" — it's "I can't follow conversations in restaurants." We cover how directional microphones, noise reduction, and multi-channel processing address this.
The 2024 Lancet standing Commission on dementia (Livingston et al.) identifies hearing loss as one of the largest potentially modifiable midlife risk factors for dementia. The 2023 ACHIEVE randomised trial (Lin et al.) tested whether a hearing intervention reduces 3-year cognitive decline. We summarise what this evidence does — and does not — show.
Trial periods, return policies, and warranties vary widely. We document what to look for and how to verify a seller's claims before purchase.
Family members are often the first to notice hearing changes. We publish education aimed at the people supporting a loved one through a buying decision.